Page last updated: 2024-12-05

pd 169316

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

2-(4-nitrophenyl)-4-(4-fluorophenyl)-5-(4-pyridinyl)-1H-imidazole: p38 MAP kinase inhibitor [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID4712
CHEMBL ID17331
CHEBI ID93358
SCHEMBL ID154958
SCHEMBL ID9899161
MeSH IDM0363372

Synonyms (76)

Synonym
CBIOL_002019
pd 169316 ,
4-(4-fluorophenyl)-2-(4-nitrophenyl)-5-(4-pyridyl)-1h-imidazole
BRD-K77133231-001-01-1
EU-0100401
pd 169316, >=98% (hplc), solid
HSCI1_000116
BIO1_001283
BIO1_000305
BIO1_000794
NCGC00093828-03
NCGC00093828-01
NCGC00093828-02
pd168316 ,
pd-169316
pyridine, 4-(4-(4-fluorophenyl)-2-(4-nitrophenyl)-1h-imidazol-5-yl)-
2-(4-nitrophenyl)-4-(4-fluorophenyl)-5-(4-pyridinyl)-1h-imidazole
152121-53-4
pd169316 ,
4-[4-(4-fluorophenyl)-2-(4-nitrophenyl)-1h-imidazol-5-yl]pyridine
4-[4-(4-fluorophenyl)-2-(4-nitrophenyl)-1h-imidazol-5-yl]-pyridine
NCGC00093828-04
CHEMBL17331 ,
HMS3229M10
bdbm50230001
4-[5-(4-fluoro-phenyl)-2-(4-nitro-phenyl)-3h-imidazol-4-yl]-pyridine
4-(4-(4-fluorophenyl)-2-(4-nitrophenyl)-1h-imidazol-5-yl)pyridine
A25448
NCGC00093828-05
HMS3261A04
AKOS015994573
BCP9001064
FT-0673539
BCPP000122
LP00401
S5183
AKOS016340706
gtpl6016
CCG-206874
CCG-221705
HY-10578
CS-1711
BGIYKDUASORTBB-UHFFFAOYSA-N ,
SCHEMBL154958
ES-0028
NCGC00261086-01
tox21_500401
DTXSID8042684
c20h13fn4o2
SCHEMBL9899161
j1.342.800j ,
GX3Y2V80CV ,
pyridine, 4-(5-(4-fluorophenyl)-2-(4-nitrophenyl)-1h-imidazol-4-yl)-
AC-31396
AKOS024464733
HMS3649N16
mfcd12405019
J-514243
EX-A219
CHEBI:93358
unii-gx3y2v80cv
J-008892
NCGC00093828-06
pd 169,316
pyridine,4-[4-(4-fluorophenyl)-2-(4-nitrophenyl)-1h-imidazol-5-yl]-
pd 169316 - cas 152121-53-4
4-(5-(4-fluorophenyl)-2-(4-nitrophenyl)-1h-imidazol-4-yl)pyridine
Q27088275
P2532
SR-01000838075-3
sr-01000838075
BCP02234
SDCCGSBI-0086779.P002
NCGC00093828-14
4-[5-(4-fluorophenyl)-2-(4-nitrophenyl)-1h-imidazol-4-yl]-pyridine
SY235161

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
imidazolesA five-membered organic heterocycle containing two nitrogen atoms at positions 1 and 3, or any of its derivatives; compounds containing an imidazole skeleton.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (62)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASEHomo sapiens (human)Potency44.66840.003245.467312,589.2998AID2517
Chain A, TYROSYL-DNA PHOSPHODIESTERASEHomo sapiens (human)Potency36.04150.004023.8416100.0000AID485290
Chain A, ATP-DEPENDENT DNA HELICASE Q1Homo sapiens (human)Potency3.16230.125919.1169125.8920AID2353
Chain A, CruzipainTrypanosoma cruziPotency0.02510.002014.677939.8107AID1476
thioredoxin reductaseRattus norvegicus (Norway rat)Potency44.66840.100020.879379.4328AID588456
15-lipoxygenase, partialHomo sapiens (human)Potency0.10000.012610.691788.5700AID887
ATAD5 protein, partialHomo sapiens (human)Potency22.71720.004110.890331.5287AID493106; AID493107
USP1 protein, partialHomo sapiens (human)Potency50.11870.031637.5844354.8130AID504865
NFKB1 protein, partialHomo sapiens (human)Potency12.58930.02827.055915.8489AID895; AID928
PPM1D proteinHomo sapiens (human)Potency32.99930.00529.466132.9993AID1347411
Microtubule-associated protein tauHomo sapiens (human)Potency8.47190.180013.557439.8107AID1460; AID1468
ThrombopoietinHomo sapiens (human)Potency12.58930.02517.304831.6228AID917; AID918
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency35.48130.011212.4002100.0000AID1030
regulator of G-protein signaling 4Homo sapiens (human)Potency0.84290.531815.435837.6858AID504845
nonstructural protein 1Influenza A virus (A/WSN/1933(H1N1))Potency1.41250.28189.721235.4813AID2326
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency13.39220.001530.607315,848.9004AID1224819; AID1224820; AID1224821
arylsulfatase AHomo sapiens (human)Potency8.49211.069113.955137.9330AID720538
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency22.47380.035520.977089.1251AID504332
Bloom syndrome protein isoform 1Homo sapiens (human)Potency19.95260.540617.639296.1227AID2364; AID2528
peripheral myelin protein 22 isoform 1Homo sapiens (human)Potency60.119823.934123.934123.9341AID1967
cellular tumor antigen p53 isoform aHomo sapiens (human)Potency0.15850.316212.443531.6228AID902
D(1A) dopamine receptorHomo sapiens (human)Potency6.51270.02245.944922.3872AID488982
chromobox protein homolog 1Homo sapiens (human)Potency31.62280.006026.168889.1251AID488953
thyroid hormone receptor beta isoform aHomo sapiens (human)Potency0.02820.010039.53711,122.0200AID1479
potassium voltage-gated channel subfamily H member 2 isoform dHomo sapiens (human)Potency8.91250.01789.637444.6684AID588834
mitogen-activated protein kinase 1Homo sapiens (human)Potency29.88160.039816.784239.8107AID1454; AID995
ras-related protein Rab-9AHomo sapiens (human)Potency58.04790.00022.621531.4954AID485297
serine/threonine-protein kinase mTOR isoform 1Homo sapiens (human)Potency5.83820.00378.618923.2809AID2667; AID2668
histone-lysine N-methyltransferase 2A isoform 2 precursorHomo sapiens (human)Potency50.11870.010323.856763.0957AID2662
peptidyl-prolyl cis-trans isomerase NIMA-interacting 1Homo sapiens (human)Potency0.03380.425612.059128.1838AID504536
gemininHomo sapiens (human)Potency12.58930.004611.374133.4983AID463097
DNA polymerase kappa isoform 1Homo sapiens (human)Potency18.88760.031622.3146100.0000AID588579
cytochrome P450 3A4 isoform 1Homo sapiens (human)Potency0.15850.031610.279239.8107AID884; AID885
M-phase phosphoprotein 8Homo sapiens (human)Potency22.38720.177824.735279.4328AID488949
muscleblind-like protein 1 isoform 1Homo sapiens (human)Potency17.78280.00419.962528.1838AID2675
histone acetyltransferase KAT2A isoform 1Homo sapiens (human)Potency39.81070.251215.843239.8107AID504327
muscarinic acetylcholine receptor M1Rattus norvegicus (Norway rat)Potency17.78280.00106.000935.4813AID944
lamin isoform A-delta10Homo sapiens (human)Potency6.29690.891312.067628.1838AID1459; AID1487
neuropeptide S receptor isoform AHomo sapiens (human)Potency7.94330.015812.3113615.5000AID1461
Gamma-aminobutyric acid receptor subunit piRattus norvegicus (Norway rat)Potency0.15851.000012.224831.6228AID885
Polyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)Potency31.62280.316212.765731.6228AID881
Interferon betaHomo sapiens (human)Potency32.99930.00339.158239.8107AID1347411
Gamma-aminobutyric acid receptor subunit beta-1Rattus norvegicus (Norway rat)Potency0.15851.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit deltaRattus norvegicus (Norway rat)Potency0.15851.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)Potency0.15851.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-5Rattus norvegicus (Norway rat)Potency0.15851.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-3Rattus norvegicus (Norway rat)Potency0.15851.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-1Rattus norvegicus (Norway rat)Potency0.15851.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-2Rattus norvegicus (Norway rat)Potency0.15851.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-4Rattus norvegicus (Norway rat)Potency0.15851.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-3Rattus norvegicus (Norway rat)Potency0.15851.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-6Rattus norvegicus (Norway rat)Potency0.15851.000012.224831.6228AID885
Alpha-synucleinHomo sapiens (human)Potency9.20000.56239.398525.1189AID652106
Histamine H2 receptorCavia porcellus (domestic guinea pig)Potency31.62280.00638.235039.8107AID881
D(1A) dopamine receptorSus scrofa (pig)Potency0.00830.00378.108123.2809AID2667
Gamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)Potency0.15851.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-3Rattus norvegicus (Norway rat)Potency0.15851.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)Potency0.15851.000012.224831.6228AID885
GABA theta subunitRattus norvegicus (Norway rat)Potency0.15851.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit epsilonRattus norvegicus (Norway rat)Potency0.15851.000012.224831.6228AID885
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
TyrosinaseMus musculus (house mouse)IC50 (µMol)0.08900.03002.21045.2300AID1611955
Mitogen-activated protein kinase 14Homo sapiens (human)IC50 (µMol)0.08900.00010.72667.8000AID1732391
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (189)

Processvia Protein(s)Taxonomy
lipid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
phospholipid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
apoptotic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
negative regulation of cell population proliferationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
positive regulation of macrophage derived foam cell differentiationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
arachidonic acid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
negative regulation of cell migrationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
prostate gland developmentPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
regulation of epithelial cell differentiationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
positive regulation of chemokine productionPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
positive regulation of peroxisome proliferator activated receptor signaling pathwayPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
positive regulation of keratinocyte differentiationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
negative regulation of cell cyclePolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
negative regulation of growthPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
hepoxilin biosynthetic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
endocannabinoid signaling pathwayPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
cannabinoid biosynthetic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
lipoxin A4 biosynthetic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
linoleic acid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
lipid oxidationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
lipoxygenase pathwayPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell activation involved in immune responseInterferon betaHomo sapiens (human)
cell surface receptor signaling pathwayInterferon betaHomo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to virusInterferon betaHomo sapiens (human)
positive regulation of autophagyInterferon betaHomo sapiens (human)
cytokine-mediated signaling pathwayInterferon betaHomo sapiens (human)
natural killer cell activationInterferon betaHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylation of STAT proteinInterferon betaHomo sapiens (human)
cellular response to interferon-betaInterferon betaHomo sapiens (human)
B cell proliferationInterferon betaHomo sapiens (human)
negative regulation of viral genome replicationInterferon betaHomo sapiens (human)
innate immune responseInterferon betaHomo sapiens (human)
positive regulation of innate immune responseInterferon betaHomo sapiens (human)
regulation of MHC class I biosynthetic processInterferon betaHomo sapiens (human)
negative regulation of T cell differentiationInterferon betaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIInterferon betaHomo sapiens (human)
defense response to virusInterferon betaHomo sapiens (human)
type I interferon-mediated signaling pathwayInterferon betaHomo sapiens (human)
neuron cellular homeostasisInterferon betaHomo sapiens (human)
cellular response to exogenous dsRNAInterferon betaHomo sapiens (human)
cellular response to virusInterferon betaHomo sapiens (human)
negative regulation of Lewy body formationInterferon betaHomo sapiens (human)
negative regulation of T-helper 2 cell cytokine productionInterferon betaHomo sapiens (human)
positive regulation of apoptotic signaling pathwayInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell differentiationInterferon betaHomo sapiens (human)
natural killer cell activation involved in immune responseInterferon betaHomo sapiens (human)
adaptive immune responseInterferon betaHomo sapiens (human)
T cell activation involved in immune responseInterferon betaHomo sapiens (human)
humoral immune responseInterferon betaHomo sapiens (human)
calcium ion homeostasisAlpha-synucleinHomo sapiens (human)
negative regulation of transcription by RNA polymerase IIAlpha-synucleinHomo sapiens (human)
microglial cell activationAlpha-synucleinHomo sapiens (human)
positive regulation of receptor recyclingAlpha-synucleinHomo sapiens (human)
positive regulation of neurotransmitter secretionAlpha-synucleinHomo sapiens (human)
negative regulation of protein kinase activityAlpha-synucleinHomo sapiens (human)
fatty acid metabolic processAlpha-synucleinHomo sapiens (human)
neutral lipid metabolic processAlpha-synucleinHomo sapiens (human)
phospholipid metabolic processAlpha-synucleinHomo sapiens (human)
activation of cysteine-type endopeptidase activity involved in apoptotic processAlpha-synucleinHomo sapiens (human)
mitochondrial membrane organizationAlpha-synucleinHomo sapiens (human)
adult locomotory behaviorAlpha-synucleinHomo sapiens (human)
response to xenobiotic stimulusAlpha-synucleinHomo sapiens (human)
response to iron(II) ionAlpha-synucleinHomo sapiens (human)
regulation of phospholipase activityAlpha-synucleinHomo sapiens (human)
negative regulation of platelet-derived growth factor receptor signaling pathwayAlpha-synucleinHomo sapiens (human)
regulation of glutamate secretionAlpha-synucleinHomo sapiens (human)
regulation of dopamine secretionAlpha-synucleinHomo sapiens (human)
synaptic vesicle exocytosisAlpha-synucleinHomo sapiens (human)
synaptic vesicle primingAlpha-synucleinHomo sapiens (human)
regulation of transmembrane transporter activityAlpha-synucleinHomo sapiens (human)
negative regulation of microtubule polymerizationAlpha-synucleinHomo sapiens (human)
receptor internalizationAlpha-synucleinHomo sapiens (human)
protein destabilizationAlpha-synucleinHomo sapiens (human)
response to magnesium ionAlpha-synucleinHomo sapiens (human)
negative regulation of transporter activityAlpha-synucleinHomo sapiens (human)
response to lipopolysaccharideAlpha-synucleinHomo sapiens (human)
negative regulation of monooxygenase activityAlpha-synucleinHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylationAlpha-synucleinHomo sapiens (human)
response to type II interferonAlpha-synucleinHomo sapiens (human)
cellular response to oxidative stressAlpha-synucleinHomo sapiens (human)
SNARE complex assemblyAlpha-synucleinHomo sapiens (human)
positive regulation of SNARE complex assemblyAlpha-synucleinHomo sapiens (human)
regulation of locomotionAlpha-synucleinHomo sapiens (human)
dopamine biosynthetic processAlpha-synucleinHomo sapiens (human)
mitochondrial ATP synthesis coupled electron transportAlpha-synucleinHomo sapiens (human)
regulation of macrophage activationAlpha-synucleinHomo sapiens (human)
positive regulation of apoptotic processAlpha-synucleinHomo sapiens (human)
negative regulation of apoptotic processAlpha-synucleinHomo sapiens (human)
negative regulation of cysteine-type endopeptidase activity involved in apoptotic processAlpha-synucleinHomo sapiens (human)
negative regulation of neuron apoptotic processAlpha-synucleinHomo sapiens (human)
positive regulation of endocytosisAlpha-synucleinHomo sapiens (human)
negative regulation of exocytosisAlpha-synucleinHomo sapiens (human)
positive regulation of exocytosisAlpha-synucleinHomo sapiens (human)
regulation of long-term neuronal synaptic plasticityAlpha-synucleinHomo sapiens (human)
synaptic vesicle endocytosisAlpha-synucleinHomo sapiens (human)
synaptic vesicle transportAlpha-synucleinHomo sapiens (human)
positive regulation of inflammatory responseAlpha-synucleinHomo sapiens (human)
regulation of acyl-CoA biosynthetic processAlpha-synucleinHomo sapiens (human)
protein tetramerizationAlpha-synucleinHomo sapiens (human)
positive regulation of release of sequestered calcium ion into cytosolAlpha-synucleinHomo sapiens (human)
neuron apoptotic processAlpha-synucleinHomo sapiens (human)
dopamine uptake involved in synaptic transmissionAlpha-synucleinHomo sapiens (human)
negative regulation of dopamine uptake involved in synaptic transmissionAlpha-synucleinHomo sapiens (human)
negative regulation of serotonin uptakeAlpha-synucleinHomo sapiens (human)
regulation of norepinephrine uptakeAlpha-synucleinHomo sapiens (human)
negative regulation of norepinephrine uptakeAlpha-synucleinHomo sapiens (human)
excitatory postsynaptic potentialAlpha-synucleinHomo sapiens (human)
long-term synaptic potentiationAlpha-synucleinHomo sapiens (human)
positive regulation of inositol phosphate biosynthetic processAlpha-synucleinHomo sapiens (human)
negative regulation of thrombin-activated receptor signaling pathwayAlpha-synucleinHomo sapiens (human)
response to interleukin-1Alpha-synucleinHomo sapiens (human)
cellular response to copper ionAlpha-synucleinHomo sapiens (human)
cellular response to epinephrine stimulusAlpha-synucleinHomo sapiens (human)
positive regulation of protein serine/threonine kinase activityAlpha-synucleinHomo sapiens (human)
supramolecular fiber organizationAlpha-synucleinHomo sapiens (human)
negative regulation of mitochondrial electron transport, NADH to ubiquinoneAlpha-synucleinHomo sapiens (human)
positive regulation of glutathione peroxidase activityAlpha-synucleinHomo sapiens (human)
positive regulation of hydrogen peroxide catabolic processAlpha-synucleinHomo sapiens (human)
regulation of synaptic vesicle recyclingAlpha-synucleinHomo sapiens (human)
regulation of reactive oxygen species biosynthetic processAlpha-synucleinHomo sapiens (human)
positive regulation of protein localization to cell peripheryAlpha-synucleinHomo sapiens (human)
negative regulation of chaperone-mediated autophagyAlpha-synucleinHomo sapiens (human)
regulation of presynapse assemblyAlpha-synucleinHomo sapiens (human)
amyloid fibril formationAlpha-synucleinHomo sapiens (human)
synapse organizationAlpha-synucleinHomo sapiens (human)
chemical synaptic transmissionAlpha-synucleinHomo sapiens (human)
positive regulation of blood vessel endothelial cell migrationMitogen-activated protein kinase 14Homo sapiens (human)
cellular response to lipopolysaccharideMitogen-activated protein kinase 14Homo sapiens (human)
DNA damage checkpoint signalingMitogen-activated protein kinase 14Homo sapiens (human)
cell morphogenesisMitogen-activated protein kinase 14Homo sapiens (human)
cartilage condensationMitogen-activated protein kinase 14Homo sapiens (human)
angiogenesisMitogen-activated protein kinase 14Homo sapiens (human)
osteoblast differentiationMitogen-activated protein kinase 14Homo sapiens (human)
placenta developmentMitogen-activated protein kinase 14Homo sapiens (human)
response to dietary excessMitogen-activated protein kinase 14Homo sapiens (human)
chondrocyte differentiationMitogen-activated protein kinase 14Homo sapiens (human)
negative regulation of inflammatory response to antigenic stimulusMitogen-activated protein kinase 14Homo sapiens (human)
glucose metabolic processMitogen-activated protein kinase 14Homo sapiens (human)
regulation of transcription by RNA polymerase IIMitogen-activated protein kinase 14Homo sapiens (human)
transcription by RNA polymerase IIMitogen-activated protein kinase 14Homo sapiens (human)
apoptotic processMitogen-activated protein kinase 14Homo sapiens (human)
chemotaxisMitogen-activated protein kinase 14Homo sapiens (human)
signal transductionMitogen-activated protein kinase 14Homo sapiens (human)
cell surface receptor signaling pathwayMitogen-activated protein kinase 14Homo sapiens (human)
cell surface receptor protein serine/threonine kinase signaling pathwayMitogen-activated protein kinase 14Homo sapiens (human)
skeletal muscle tissue developmentMitogen-activated protein kinase 14Homo sapiens (human)
positive regulation of gene expressionMitogen-activated protein kinase 14Homo sapiens (human)
positive regulation of myotube differentiationMitogen-activated protein kinase 14Homo sapiens (human)
peptidyl-serine phosphorylationMitogen-activated protein kinase 14Homo sapiens (human)
fatty acid oxidationMitogen-activated protein kinase 14Homo sapiens (human)
platelet activationMitogen-activated protein kinase 14Homo sapiens (human)
regulation of ossificationMitogen-activated protein kinase 14Homo sapiens (human)
osteoclast differentiationMitogen-activated protein kinase 14Homo sapiens (human)
stress-activated protein kinase signaling cascadeMitogen-activated protein kinase 14Homo sapiens (human)
positive regulation of cyclase activityMitogen-activated protein kinase 14Homo sapiens (human)
lipopolysaccharide-mediated signaling pathwayMitogen-activated protein kinase 14Homo sapiens (human)
response to muramyl dipeptideMitogen-activated protein kinase 14Homo sapiens (human)
positive regulation of interleukin-12 productionMitogen-activated protein kinase 14Homo sapiens (human)
response to insulinMitogen-activated protein kinase 14Homo sapiens (human)
negative regulation of hippo signalingMitogen-activated protein kinase 14Homo sapiens (human)
intracellular signal transductionMitogen-activated protein kinase 14Homo sapiens (human)
cellular response to vascular endothelial growth factor stimulusMitogen-activated protein kinase 14Homo sapiens (human)
response to muscle stretchMitogen-activated protein kinase 14Homo sapiens (human)
p38MAPK cascadeMitogen-activated protein kinase 14Homo sapiens (human)
positive regulation of protein import into nucleusMitogen-activated protein kinase 14Homo sapiens (human)
signal transduction in response to DNA damageMitogen-activated protein kinase 14Homo sapiens (human)
positive regulation of erythrocyte differentiationMitogen-activated protein kinase 14Homo sapiens (human)
positive regulation of myoblast differentiationMitogen-activated protein kinase 14Homo sapiens (human)
positive regulation of transcription by RNA polymerase IIMitogen-activated protein kinase 14Homo sapiens (human)
glucose importMitogen-activated protein kinase 14Homo sapiens (human)
positive regulation of glucose importMitogen-activated protein kinase 14Homo sapiens (human)
vascular endothelial growth factor receptor signaling pathwayMitogen-activated protein kinase 14Homo sapiens (human)
stem cell differentiationMitogen-activated protein kinase 14Homo sapiens (human)
striated muscle cell differentiationMitogen-activated protein kinase 14Homo sapiens (human)
positive regulation of muscle cell differentiationMitogen-activated protein kinase 14Homo sapiens (human)
stress-activated MAPK cascadeMitogen-activated protein kinase 14Homo sapiens (human)
positive regulation of cardiac muscle cell proliferationMitogen-activated protein kinase 14Homo sapiens (human)
bone developmentMitogen-activated protein kinase 14Homo sapiens (human)
3'-UTR-mediated mRNA stabilizationMitogen-activated protein kinase 14Homo sapiens (human)
cellular response to lipoteichoic acidMitogen-activated protein kinase 14Homo sapiens (human)
cellular response to tumor necrosis factorMitogen-activated protein kinase 14Homo sapiens (human)
cellular response to ionizing radiationMitogen-activated protein kinase 14Homo sapiens (human)
cellular response to UV-BMitogen-activated protein kinase 14Homo sapiens (human)
negative regulation of canonical Wnt signaling pathwayMitogen-activated protein kinase 14Homo sapiens (human)
positive regulation of brown fat cell differentiationMitogen-activated protein kinase 14Homo sapiens (human)
cellular senescenceMitogen-activated protein kinase 14Homo sapiens (human)
stress-induced premature senescenceMitogen-activated protein kinase 14Homo sapiens (human)
cellular response to virusMitogen-activated protein kinase 14Homo sapiens (human)
regulation of synaptic membrane adhesionMitogen-activated protein kinase 14Homo sapiens (human)
regulation of cytokine production involved in inflammatory responseMitogen-activated protein kinase 14Homo sapiens (human)
positive regulation of myoblast fusionMitogen-activated protein kinase 14Homo sapiens (human)
positive regulation of reactive oxygen species metabolic processMitogen-activated protein kinase 14Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (44)

Processvia Protein(s)Taxonomy
iron ion bindingPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
calcium ion bindingPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
protein bindingPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
lipid bindingPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
linoleate 13S-lipoxygenase activityPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
arachidonate 8(S)-lipoxygenase activityPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
arachidonate 15-lipoxygenase activityPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
linoleate 9S-lipoxygenase activityPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
cytokine activityInterferon betaHomo sapiens (human)
cytokine receptor bindingInterferon betaHomo sapiens (human)
type I interferon receptor bindingInterferon betaHomo sapiens (human)
protein bindingInterferon betaHomo sapiens (human)
chloramphenicol O-acetyltransferase activityInterferon betaHomo sapiens (human)
fatty acid bindingAlpha-synucleinHomo sapiens (human)
phospholipase D inhibitor activityAlpha-synucleinHomo sapiens (human)
SNARE bindingAlpha-synucleinHomo sapiens (human)
magnesium ion bindingAlpha-synucleinHomo sapiens (human)
transcription cis-regulatory region bindingAlpha-synucleinHomo sapiens (human)
actin bindingAlpha-synucleinHomo sapiens (human)
protein kinase inhibitor activityAlpha-synucleinHomo sapiens (human)
copper ion bindingAlpha-synucleinHomo sapiens (human)
calcium ion bindingAlpha-synucleinHomo sapiens (human)
protein bindingAlpha-synucleinHomo sapiens (human)
phospholipid bindingAlpha-synucleinHomo sapiens (human)
ferrous iron bindingAlpha-synucleinHomo sapiens (human)
zinc ion bindingAlpha-synucleinHomo sapiens (human)
lipid bindingAlpha-synucleinHomo sapiens (human)
oxidoreductase activityAlpha-synucleinHomo sapiens (human)
kinesin bindingAlpha-synucleinHomo sapiens (human)
Hsp70 protein bindingAlpha-synucleinHomo sapiens (human)
histone bindingAlpha-synucleinHomo sapiens (human)
identical protein bindingAlpha-synucleinHomo sapiens (human)
alpha-tubulin bindingAlpha-synucleinHomo sapiens (human)
cysteine-type endopeptidase inhibitor activity involved in apoptotic processAlpha-synucleinHomo sapiens (human)
tau protein bindingAlpha-synucleinHomo sapiens (human)
phosphoprotein bindingAlpha-synucleinHomo sapiens (human)
molecular adaptor activityAlpha-synucleinHomo sapiens (human)
dynein complex bindingAlpha-synucleinHomo sapiens (human)
cuprous ion bindingAlpha-synucleinHomo sapiens (human)
protein serine/threonine kinase activityMitogen-activated protein kinase 14Homo sapiens (human)
MAP kinase activityMitogen-activated protein kinase 14Homo sapiens (human)
MAP kinase kinase activityMitogen-activated protein kinase 14Homo sapiens (human)
protein bindingMitogen-activated protein kinase 14Homo sapiens (human)
ATP bindingMitogen-activated protein kinase 14Homo sapiens (human)
enzyme bindingMitogen-activated protein kinase 14Homo sapiens (human)
protein phosphatase bindingMitogen-activated protein kinase 14Homo sapiens (human)
mitogen-activated protein kinase p38 bindingMitogen-activated protein kinase 14Homo sapiens (human)
NFAT protein bindingMitogen-activated protein kinase 14Homo sapiens (human)
protein serine kinase activityMitogen-activated protein kinase 14Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (32)

Processvia Protein(s)Taxonomy
nucleusPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
cytosolPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
cytoskeletonPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
plasma membranePolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
adherens junctionPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
focal adhesionPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
membranePolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
extracellular exosomePolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
extracellular spaceInterferon betaHomo sapiens (human)
extracellular regionInterferon betaHomo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)
platelet alpha granule membraneAlpha-synucleinHomo sapiens (human)
extracellular regionAlpha-synucleinHomo sapiens (human)
extracellular spaceAlpha-synucleinHomo sapiens (human)
nucleusAlpha-synucleinHomo sapiens (human)
cytoplasmAlpha-synucleinHomo sapiens (human)
mitochondrionAlpha-synucleinHomo sapiens (human)
lysosomeAlpha-synucleinHomo sapiens (human)
cytosolAlpha-synucleinHomo sapiens (human)
plasma membraneAlpha-synucleinHomo sapiens (human)
cell cortexAlpha-synucleinHomo sapiens (human)
actin cytoskeletonAlpha-synucleinHomo sapiens (human)
membraneAlpha-synucleinHomo sapiens (human)
inclusion bodyAlpha-synucleinHomo sapiens (human)
axonAlpha-synucleinHomo sapiens (human)
growth coneAlpha-synucleinHomo sapiens (human)
synaptic vesicle membraneAlpha-synucleinHomo sapiens (human)
perinuclear region of cytoplasmAlpha-synucleinHomo sapiens (human)
postsynapseAlpha-synucleinHomo sapiens (human)
supramolecular fiberAlpha-synucleinHomo sapiens (human)
protein-containing complexAlpha-synucleinHomo sapiens (human)
cytoplasmAlpha-synucleinHomo sapiens (human)
axon terminusAlpha-synucleinHomo sapiens (human)
neuronal cell bodyAlpha-synucleinHomo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)
plasma membraneGamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)
cytosolMitogen-activated protein kinase 14Homo sapiens (human)
spindle poleMitogen-activated protein kinase 14Homo sapiens (human)
extracellular regionMitogen-activated protein kinase 14Homo sapiens (human)
nucleusMitogen-activated protein kinase 14Homo sapiens (human)
nucleoplasmMitogen-activated protein kinase 14Homo sapiens (human)
cytoplasmMitogen-activated protein kinase 14Homo sapiens (human)
mitochondrionMitogen-activated protein kinase 14Homo sapiens (human)
cytosolMitogen-activated protein kinase 14Homo sapiens (human)
nuclear speckMitogen-activated protein kinase 14Homo sapiens (human)
secretory granule lumenMitogen-activated protein kinase 14Homo sapiens (human)
glutamatergic synapseMitogen-activated protein kinase 14Homo sapiens (human)
ficolin-1-rich granule lumenMitogen-activated protein kinase 14Homo sapiens (human)
nucleusMitogen-activated protein kinase 14Homo sapiens (human)
cytoplasmMitogen-activated protein kinase 14Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (568)

Assay IDTitleYearJournalArticle
AID1347151Optimization of GU AMC qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID588349qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay
AID1347057CD47-SIRPalpha protein protein interaction - LANCE assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID588378qHTS for Inhibitors of ATXN expression: Validation
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1347410qHTS for inhibitors of adenylyl cyclases using a fission yeast platform: a pilot screen against the NCATS LOPAC library2019Cellular signalling, 08, Volume: 60A fission yeast platform for heterologous expression of mammalian adenylyl cyclases and high throughput screening.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347405qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS LOPAC collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID504836Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation2002The Journal of biological chemistry, Apr-19, Volume: 277, Issue:16
Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells.
AID1347049Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot screen2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347058CD47-SIRPalpha protein protein interaction - HTRF assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347059CD47-SIRPalpha protein protein interaction - Alpha assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347045Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot counterscreen GloSensor control cell line2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347050Natriuretic polypeptide receptor (hNpr2) antagonism - Pilot subtype selectivity assay2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID720152Millipore: Percentage of residual kinase activity of FGFR2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 2.5 mM MnCl22013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720405Millipore: Percentage of residual kinase activity of NTRK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720268Millipore: Percentage of residual kinase activity of SGK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720480Millipore: Percentage of residual kinase activity of PRKCD at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720201Millipore: Percentage of residual kinase activity of PRKCH at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720113Millipore: Percentage of residual kinase activity of DDR2 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 10 mM MnCl22013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720070Millipore: Percentage of residual kinase activity of CDK7 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720196Millipore: Percentage of residual kinase activity of HCK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1224770Delta TM value showing the stabilisation of JAK1~B produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID720273Millipore: Percentage of residual kinase activity of SIK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1224751Delta TM value showing the stabilisation of CAMK2A produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID720199Millipore: Percentage of residual kinase activity of PRKCZ at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720320Millipore: Percentage of residual kinase activity of MAPK9 at 1uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1% ?-mercaptoethanol2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720068Millipore: Percentage of residual kinase activity of CDK6 at 10uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720321Millipore: Percentage of residual kinase activity of MAPK9 at 10uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1% ?-mercaptoethanol2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720203Millipore: Percentage of residual kinase activity of PRKCQ at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1224767Delta TM value showing the stabilisation of DAPK3 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID720418Millipore: Percentage of residual kinase activity of YES1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720239Millipore: Percentage of residual kinase activity of ROCK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720357Millipore: Percentage of residual kinase activity of MAP2K7 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1% ?-mercaptoethanol, 0.1 mM Na3VO42013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720471Millipore: Percentage of residual kinase activity of AKT3 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720343Millipore: Percentage of residual kinase activity of MAPKAPK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Na-?-glycerophosphate pH 7.5, 0.1 mM EGTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720226Millipore: Percentage of residual kinase activity of PIM3 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 0.1% Triton X-1002013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720151Millipore: Percentage of residual kinase activity of FGFR2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 2.5 mM MnCl22013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720214Millipore: Percentage of residual kinase activity of MAPKAPK5 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Na-?-glycerophosphate pH 7.5, 0.1 mM EGTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720142Millipore: Percentage of residual kinase activity of EPHB3 at 10uM relative to control. Control inhibitor: PP2 at 30.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 10 mM MnCl22013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720044Millipore: Percentage of residual kinase activity of PTK6 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 5 mM MnCl22013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720181Millipore: Percentage of residual kinase activity of GSK3A at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720473Millipore: Percentage of residual kinase activity of PRKCA at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720210Millipore: Percentage of residual kinase activity of PRKG1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 10 uM cGMP2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720363Millipore: Percentage of residual kinase activity of CDC42BPA at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720079Millipore: Percentage of residual kinase activity of CSNK1G2 at 1uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720240Millipore: Percentage of residual kinase activity of ROCK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720385Millipore: Percentage of residual kinase activity of MUSK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 5 mM MnCl22013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1224795Delta TM value showing the stabilisation of SLK produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID720389Millipore: Percentage of residual kinase activity of NEK2 at 10uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720036Millipore: Percentage of residual kinase activity of AURKA at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 50 mM NaCl, 0.1% v/v Triton-X-1002013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1224782Delta TM value showing the stabilisation of PAK5 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID720371Millipore: Percentage of residual kinase activity of SRPK3 at 10uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720258Millipore: Percentage of residual kinase activity of MAPK14 at 1uM relative to control. Control inhibitor: SB203580 at 100.0uM. Buffer: 25 mM Tris pH 7.5, 0.02 mM EGTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720437Millipore: Percentage of residual kinase activity of RPS6KB1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720184Millipore: Percentage of residual kinase activity of GSK3B at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720414Millipore: Percentage of residual kinase activity of WNK2 at 1uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720071Millipore: Percentage of residual kinase activity of CDK9 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720301Millipore: Percentage of residual kinase activity of IKBKB at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720466Millipore: Percentage of residual kinase activity of AKT1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720286Millipore: Percentage of residual kinase activity of TAOK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 50 mM NaCl2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720138Millipore: Percentage of residual kinase activity of EPHB1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720234Millipore: Percentage of residual kinase activity of PTK2B at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1224790Delta TM value showing the stabilisation of PLK4 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID720193Millipore: Percentage of residual kinase activity of HCK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720153Millipore: Percentage of residual kinase activity of FGFR3 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720204Millipore: Percentage of residual kinase activity of PRKCI at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-1002013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720452Millipore: Percentage of residual kinase activity of PAK6 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720228Millipore: Percentage of residual kinase activity of PLK1 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 20 mM DTT2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720419Millipore: Percentage of residual kinase activity of YES1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720065Millipore: Percentage of residual kinase activity of CDK5 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720263Millipore: Percentage of residual kinase activity of MAPK12 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 25 mM Tris pH 7.5, 0.02 mM EGTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720444Millipore: Percentage of residual kinase activity of PAK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720040Millipore: Percentage of residual kinase activity of AURKC at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 50 mM NaCl, 0.1% v/v Triton-X-1002013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720165Millipore: Percentage of residual kinase activity of FLT3 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720267Millipore: Percentage of residual kinase activity of SGK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720055Millipore: Percentage of residual kinase activity of CDK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720120Millipore: Percentage of residual kinase activity of DYRK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720115Millipore: Percentage of residual kinase activity of DMPK at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720455Millipore: Percentage of residual kinase activity of MARK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720108Millipore: Percentage of residual kinase activity of DAPK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1224798Delta TM value showing the stabilisation of DRAK1 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1224788Delta TM value showing the stabilisation of PIM3 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID720300Millipore: Percentage of residual kinase activity of IKBKB at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720291Millipore: Percentage of residual kinase activity of TAOK3 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 200 mM NaCl, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720406Millipore: Percentage of residual kinase activity of TXK at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720242Millipore: Percentage of residual kinase activity of RET at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720157Millipore: Percentage of residual kinase activity of FER at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 1 mM MnCl22013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720148Millipore: Percentage of residual kinase activity of PTK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720428Millipore: Percentage of residual kinase activity of SRC at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720231Millipore: Percentage of residual kinase activity of PLK3 at 10uM relative to control. Control inhibitor: Wortmannin at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720246Millipore: Percentage of residual kinase activity of ROS1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 10 mM MnCl22013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720245Millipore: Percentage of residual kinase activity of MST1R at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720029Millipore: Percentage of residual kinase activity of MAP3K5 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720208Millipore: Percentage of residual kinase activity of PRKD2 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-1002013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720391Millipore: Percentage of residual kinase activity of NEK3 at 10uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720149Millipore: Percentage of residual kinase activity of FGFR1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1224773Delta TM value showing the stabilisation of ASK1 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID720346Millipore: Percentage of residual kinase activity of MARK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720189Millipore: Percentage of residual kinase activity of HIPK3 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1224755Delta TM value showing the stabilisation of CAMK4 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID720147Millipore: Percentage of residual kinase activity of PTK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720025Millipore: Percentage of residual kinase activity of PRKAA2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 200 uM AMP2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720105Millipore: Percentage of residual kinase activity of CAMK1D at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 0.5 mM CaCl2, 16 ug/mL calmodulin2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720407Millipore: Percentage of residual kinase activity of TXK at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720308Millipore: Percentage of residual kinase activity of IRAK4 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720388Millipore: Percentage of residual kinase activity of NEK2 at 1uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720154Millipore: Percentage of residual kinase activity of FGFR3 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720348Millipore: Percentage of residual kinase activity of MAP2K1 at 1uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 50 mM Tris pH 7.5, 0.2 mM EGTA, 0.1% ?-mercaptoethanol, 0.01% Brij-352013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720269Millipore: Percentage of residual kinase activity of SGK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720191Millipore: Percentage of residual kinase activity of GSG2 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720074Millipore: Percentage of residual kinase activity of CHEK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720212Millipore: Percentage of residual kinase activity of PRKG1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 10 uM cGMP2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720310Millipore: Percentage of residual kinase activity of INSRR at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720350Millipore: Percentage of residual kinase activity of MELK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1224774Delta TM value showing the stabilisation of p38beta produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID720022Millipore: Percentage of residual kinase activity of ACVR1B at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720163Millipore: Percentage of residual kinase activity of FLT1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720472Millipore: Percentage of residual kinase activity of PRKCA at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720315Millipore: Percentage of residual kinase activity of JAK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720442Millipore: Percentage of residual kinase activity of NLK at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720275Millipore: Percentage of residual kinase activity of SRPK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720066Millipore: Percentage of residual kinase activity of CDK5 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720351Millipore: Percentage of residual kinase activity of MELK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1732391Inhibition of p38 alpha (unknown origin)
AID720085Millipore: Percentage of residual kinase activity of CSNK2A1 at 1uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-1002013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1224764Delta TM value showing the stabilisation of CK1G1 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1224780Delta TM value showing the stabilisation of OSR1 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID720235Millipore: Percentage of residual kinase activity of PTK2B at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720335Millipore: Percentage of residual kinase activity of LCK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1224768Delta TM value showing the stabilisation of DMPK1 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID720206Millipore: Percentage of residual kinase activity of PRKD1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: mM HEPES pH 7.4, 0.03% Triton X-1002013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720156Millipore: Percentage of residual kinase activity of FGFR4 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 10 mM MnCl22013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720396Millipore: Percentage of residual kinase activity of TSSK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720018Millipore: Percentage of residual kinase activity of TNK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720479Millipore: Percentage of residual kinase activity of PRKCG at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720461Millipore: Percentage of residual kinase activity of PDGFRB at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720097Millipore: Percentage of residual kinase activity of CAMK2B at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 0.5 mM CaCl2, 16 ug/mL calmodulin2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720192Millipore: Percentage of residual kinase activity of GSG2 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1224778Delta TM value showing the stabilisation of NEK2 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID720261Millipore: Percentage of residual kinase activity of MAPK11 at 10uM relative to control. Control inhibitor: SB203580 at 100.0uM. Buffer: 25 mM Tris pH 7.5, 0.02 mM EGTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720359Millipore: Percentage of residual kinase activity of MYLK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 0.5 mM CaCl2, 16 ug/mL calmodulin2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720076Millipore: Percentage of residual kinase activity of CHEK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720482Millipore: Percentage of residual kinase activity of PRKCE at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720023Millipore: Percentage of residual kinase activity of PRKAA1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 200 uM AMP2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720390Millipore: Percentage of residual kinase activity of NEK3 at 1uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720027Millipore: Percentage of residual kinase activity of NUAK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720062Millipore: Percentage of residual kinase activity of CDK3 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1224787Delta TM value showing the stabilisation of PIM2 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID720104Millipore: Percentage of residual kinase activity of CAMK4 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 40 mM HEPES pH 7.4, 5 mM CaCl2, 30 ug/mL calmodulin2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720364Millipore: Percentage of residual kinase activity of CDC42BPB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720296Millipore: Percentage of residual kinase activity of IGF1R at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 1 mM Na3VO4, 5 mM Na-?-glycerophosphate2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720131Millipore: Percentage of residual kinase activity of EPHA5 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 2.5 mM MnCl22013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720317Millipore: Percentage of residual kinase activity of JAK3 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720174Millipore: Percentage of residual kinase activity of GCK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 200 mM NaCl, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720367Millipore: Percentage of residual kinase activity of RPS6KA5 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720327Millipore: Percentage of residual kinase activity of LIMK1 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1224793Delta TM value showing the stabilisation of RSK2a produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID720476Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720274Millipore: Percentage of residual kinase activity of SRPK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720349Millipore: Percentage of residual kinase activity of MAP2K1 at 10uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 50 mM Tris pH 7.5, 0.2 mM EGTA, 0.1% ?-mercaptoethanol, 0.01% Brij-352013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720162Millipore: Percentage of residual kinase activity of FGR at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720215Millipore: Percentage of residual kinase activity of MAPKAPK5 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Na-?-glycerophosphate pH 7.5, 0.1 mM EGTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720421Millipore: Percentage of residual kinase activity of ZAP70 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1 mM Na3VO4, 0.1% ?-mercaptoethanol2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720465Millipore: Percentage of residual kinase activity of PRKACA at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720218Millipore: Percentage of residual kinase activity of FRK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720075Millipore: Percentage of residual kinase activity of CHEK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720259Millipore: Percentage of residual kinase activity of MAPK14 at 10uM relative to control. Control inhibitor: SB203580 at 100.0uM. Buffer: 25 mM Tris pH 7.5, 0.02 mM EGTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720236Millipore: Percentage of residual kinase activity of RIPK2 at 1uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720448Millipore: Percentage of residual kinase activity of PAK4 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720294Millipore: Percentage of residual kinase activity of TGFBR1 at 1uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 1 mM MnCl22013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720468Millipore: Percentage of residual kinase activity of AKT2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720159Millipore: Percentage of residual kinase activity of FES at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720118Millipore: Percentage of residual kinase activity of STK17A at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720133Millipore: Percentage of residual kinase activity of EPHA7 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720103Millipore: Percentage of residual kinase activity of CAMK4 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 40 mM HEPES pH 7.4, 5 mM CaCl2, 30 ug/mL calmodulin2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720387Millipore: Percentage of residual kinase activity of NEK11 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720255Millipore: Percentage of residual kinase activity of RPS6KA2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720247Millipore: Percentage of residual kinase activity of ROS1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 10 mM MnCl22013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720439Millipore: Percentage of residual kinase activity of NEK6 at 10uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1224785Delta TM value showing the stabilisation of PDK1 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID720384Millipore: Percentage of residual kinase activity of MUSK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 5 mM MnCl22013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720122Millipore: Percentage of residual kinase activity of EGFR at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 10 mM MnCl22013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720046Millipore: Percentage of residual kinase activity of BTK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720139Millipore: Percentage of residual kinase activity of EPHB2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 10 mM MnCl22013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720037Millipore: Percentage of residual kinase activity of AURKB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 50 mM NaCl, 0.1% v/v Triton-X-1002013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID524796Antiplasmodial activity against Plasmodium falciparum W2 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID720266Millipore: Percentage of residual kinase activity of SGK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720423Millipore: Percentage of residual kinase activity of DAPK3 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720463Millipore: Percentage of residual kinase activity of PDPK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1% ?-mercaptoethanol2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720128Millipore: Percentage of residual kinase activity of EPHA3 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720424Millipore: Percentage of residual kinase activity of RAF1 at 1uM relative to control. Control inhibitor: SB203580 at 100.0uM. Buffer: 25 mM Tris pH 7.5, 0.02 mM EGTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720017Millipore: Percentage of residual kinase activity of TNK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720373Millipore: Percentage of residual kinase activity of STK4 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720171Millipore: Percentage of residual kinase activity of FYN at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1 mM Na3VO42013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720440Millipore: Percentage of residual kinase activity of NEK7 at 1uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720069Millipore: Percentage of residual kinase activity of CDK7 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720416Millipore: Percentage of residual kinase activity of WNK3 at 1uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720306Millipore: Percentage of residual kinase activity of IRAK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720223Millipore: Percentage of residual kinase activity of PIM1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720093Millipore: Percentage of residual kinase activity of CSK at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1 mM Na3VO4, 0.1% ?-mercaptoethanol, 10 mM MnCl22013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720470Millipore: Percentage of residual kinase activity of AKT3 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720403Millipore: Percentage of residual kinase activity of NTRK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720034Millipore: Percentage of residual kinase activity of ABL2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720048Millipore: Percentage of residual kinase activity of BLK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1 mM Na3VO4, 0.1% ?-mercaptoethanol2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1224792Delta TM value showing the stabilisation of RIOK2 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID720304Millipore: Percentage of residual kinase activity of INSR at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 1 mM Na3VO4, 5 mM Na-?-glycerophosphate2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720045Millipore: Percentage of residual kinase activity of BTK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720123Millipore: Percentage of residual kinase activity of EPHA1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720021Millipore: Percentage of residual kinase activity of ACVR1B at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720030Millipore: Percentage of residual kinase activity of MAP3K5 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720179Millipore: Percentage of residual kinase activity of GRK7 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720356Millipore: Percentage of residual kinase activity of MAP2K7 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1% ?-mercaptoethanol, 0.1 mM Na3VO42013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720256Millipore: Percentage of residual kinase activity of RPS6KA6 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 30 mM NaCl2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720238Millipore: Percentage of residual kinase activity of ROCK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720077Millipore: Percentage of residual kinase activity of CSNK1G1 at 1uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720395Millipore: Percentage of residual kinase activity of TSSK1B at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720190Millipore: Percentage of residual kinase activity of HIPK3 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720311Millipore: Percentage of residual kinase activity of INSRR at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720368Millipore: Percentage of residual kinase activity of RPS6KA4 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720038Millipore: Percentage of residual kinase activity of AURKB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 50 mM NaCl, 0.1% v/v Triton-X-1002013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720243Millipore: Percentage of residual kinase activity of RET at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720457Millipore: Percentage of residual kinase activity of PASK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720170Millipore: Percentage of residual kinase activity of CSF1R at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720478Millipore: Percentage of residual kinase activity of PRKCG at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720278Millipore: Percentage of residual kinase activity of STK33 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720146Millipore: Percentage of residual kinase activity of ERBB4 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 2.5 mM MnCl22013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720361Millipore: Percentage of residual kinase activity of MAP3K9 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720467Millipore: Percentage of residual kinase activity of AKT1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720435Millipore: Percentage of residual kinase activity of MTOR at 10uM relative to control. Control inhibitor: Rapamycin at 10.0uM. Buffer: 50 mM HEPES pH 7.5, 1 mM EGTA, 0.01% Tween 20, 10 uM FKBP122013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720028Millipore: Percentage of residual kinase activity of NUAK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720106Millipore: Percentage of residual kinase activity of CAMK1D at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 0.5 mM CaCl2, 16 ug/mL calmodulin2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720140Millipore: Percentage of residual kinase activity of EPHB2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 10 mM MnCl22013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720082Millipore: Percentage of residual kinase activity of CSNK1G3 at 10uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720096Millipore: Percentage of residual kinase activity of CAMK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 0.5 mM CaCl2, 16 ug/mL calmodulin2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720475Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720354Millipore: Percentage of residual kinase activity of MAP2K6 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1% ?-mercaptoethanol, 0.1 mM Na3VO4, 1 mg/mL BSA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720319Millipore: Percentage of residual kinase activity of MAPK8 at 10uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1% ? -mercaptoethanol2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1224754Delta TM value showing the stabilisation of CAMK2G produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID720081Millipore: Percentage of residual kinase activity of CSNK1G3 at 1uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720460Millipore: Percentage of residual kinase activity of PDGFRB at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720483Millipore: Percentage of residual kinase activity of PRKCE at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID524795Antiplasmodial activity against Plasmodium falciparum HB3 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID720431Millipore: Percentage of residual kinase activity of EEF2K at 10uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1224784Delta TM value showing the stabilisation of PCTK1 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID720033Millipore: Percentage of residual kinase activity of ABL2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1224803Delta TM value showing the stabilisation of PBK produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID720032Millipore: Percentage of residual kinase activity of ABL1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720064Millipore: Percentage of residual kinase activity of CDK5 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720360Millipore: Percentage of residual kinase activity of MAP3K9 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720101Millipore: Percentage of residual kinase activity of CAMK2D at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 0.5 mM CaCl2, 16 ug/mL calmodulin2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720376Millipore: Percentage of residual kinase activity of STK24 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720207Millipore: Percentage of residual kinase activity of PRKD1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: mM HEPES pH 7.4, 0.03% Triton X-1002013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720252Millipore: Percentage of residual kinase activity of RPS6KA3 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720047Millipore: Percentage of residual kinase activity of BLK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1 mM Na3VO4, 0.1% ?-mercaptoethanol2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720117Millipore: Percentage of residual kinase activity of STK17A at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720249Millipore: Percentage of residual kinase activity of TYRO3 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 1 mM MnCl22013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720436Millipore: Percentage of residual kinase activity of RPS6KB1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID524791Antiplasmodial activity against Plasmodium falciparum 7G8 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID720107Millipore: Percentage of residual kinase activity of DAPK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720052Millipore: Percentage of residual kinase activity of BRSK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1224775Delta TM value showing the stabilisation of ERK1 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID720050Millipore: Percentage of residual kinase activity of BMX at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720178Millipore: Percentage of residual kinase activity of GRK6 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720213Millipore: Percentage of residual kinase activity of PRKG1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 10 uM cGMP2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1224799Delta TM value showing the stabilisation of NDR1 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1224757Delta TM value showing the stabilisation of CDK2 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID720464Millipore: Percentage of residual kinase activity of PRKACA at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720400Millipore: Percentage of residual kinase activity of TEK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 0.5 mM MnCl22013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720173Millipore: Percentage of residual kinase activity of GCK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 200 mM NaCl, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID524794Antiplasmodial activity against Plasmodium falciparum GB4 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID720295Millipore: Percentage of residual kinase activity of TGFBR1 at 10uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 1 mM MnCl22013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720119Millipore: Percentage of residual kinase activity of DYRK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID524792Antiplasmodial activity against Plasmodium falciparum D10 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID720453Millipore: Percentage of residual kinase activity of PAK6 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720150Millipore: Percentage of residual kinase activity of FGFR1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720481Millipore: Percentage of residual kinase activity of PRKCD at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720102Millipore: Percentage of residual kinase activity of CAMK2D at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 0.5 mM CaCl2, 16 ug/mL calmodulin2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1224748Delta TM value showing the stabilisation of AMPKA2 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID720426Millipore: Percentage of residual kinase activity of KIT at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 10 mM MnCl22013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720127Millipore: Percentage of residual kinase activity of EPHA3 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720250Millipore: Percentage of residual kinase activity of RPS6KA1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720279Millipore: Percentage of residual kinase activity of STK33 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720340Millipore: Percentage of residual kinase activity of MAPK1 at 1uM relative to control. Control inhibitor: ERK Inhibitor II at 30.0uM. Buffer: 25 mM Tris pH 7.5, 0.02 mM EGTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID524793Antiplasmodial activity against Plasmodium falciparum Dd2 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID720333Millipore: Percentage of residual kinase activity of LCK at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1 mM Na3VO42013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720265Millipore: Percentage of residual kinase activity of MAPK13 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 25 mM Tris pH 7.5, 0.02 mM EGTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720305Millipore: Percentage of residual kinase activity of INSR at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 1 mM Na3VO4, 5 mM Na-?-glycerophosphate2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720433Millipore: Percentage of residual kinase activity of MTOR at 10uM relative to control. Control inhibitor: PI-103 at 30.0uM. Buffer: 50 mM HEPES pH 7.5, 1 mM EGTA, 0.01% Tween 202013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID497856Inhibition of human RIP2 autophosphorylation expressed in HEK293T cells2008Nature chemical biology, May, Volume: 4, Issue:5
Identification of RIP1 kinase as a specific cellular target of necrostatins.
AID720293Millipore: Percentage of residual kinase activity of TBK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720372Millipore: Percentage of residual kinase activity of STK4 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720143Millipore: Percentage of residual kinase activity of EPHB4 at 1uM relative to control. Control inhibitor: PP2 at 30.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 10 mM MnCl22013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720035Millipore: Percentage of residual kinase activity of AURKA at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 50 mM NaCl, 0.1% v/v Triton-X-1002013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720386Millipore: Percentage of residual kinase activity of NEK11 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720298Millipore: Percentage of residual kinase activity of CHUK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720100Millipore: Percentage of residual kinase activity of CAMK2G at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 0.5 mM CaCl2, 16 ug/mL calmodulin2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720264Millipore: Percentage of residual kinase activity of MAPK13 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 25 mM Tris pH 7.5, 0.02 mM EGTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720302Millipore: Percentage of residual kinase activity of INSR at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1 mM Na3VO4, 0.1% ?-mercaptoethanol2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720338Millipore: Percentage of residual kinase activity of MAPK3 at 1uM relative to control. Control inhibitor: ERK Inhibitor II at 30.0uM. Buffer: 25 mM Tris pH 7.5, 0.02 mM EGTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720332Millipore: Percentage of residual kinase activity of LCK at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1 mM Na3VO42013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1224752Delta TM value showing the stabilisation of CAMK2B produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID720331Millipore: Percentage of residual kinase activity of STK10 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720413Millipore: Percentage of residual kinase activity of VRK2 at 10uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1224772Delta TM value showing the stabilisation of MAP2K6 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID720312Millipore: Percentage of residual kinase activity of ITK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720217Millipore: Percentage of residual kinase activity of PKN2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1% ?-mercaptoethanol2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720134Millipore: Percentage of residual kinase activity of EPHA7 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720434Millipore: Percentage of residual kinase activity of MTOR at 1uM relative to control. Control inhibitor: Rapamycin at 10.0uM. Buffer: 50 mM HEPES pH 7.5, 1 mM EGTA, 0.01% Tween 20, 10 uM FKBP122013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720114Millipore: Percentage of residual kinase activity of DDR2 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 10 mM MnCl22013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720185Millipore: Percentage of residual kinase activity of HIPK1 at 1uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720098Millipore: Percentage of residual kinase activity of CAMK2B at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 0.5 mM CaCl2, 16 ug/mL calmodulin2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720158Millipore: Percentage of residual kinase activity of FER at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 1 mM MnCl22013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720109Millipore: Percentage of residual kinase activity of DAPK2 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720136Millipore: Percentage of residual kinase activity of EPHA8 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720222Millipore: Percentage of residual kinase activity of PIM1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720318Millipore: Percentage of residual kinase activity of MAPK8 at 1uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1% ? -mercaptoethanol2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720194Millipore: Percentage of residual kinase activity of HCK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720462Millipore: Percentage of residual kinase activity of PDPK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1% ?-mercaptoethanol2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720430Millipore: Percentage of residual kinase activity of EEF2K at 1uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720230Millipore: Percentage of residual kinase activity of PLK3 at 1uM relative to control. Control inhibitor: Wortmannin at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1224763Delta TM value showing the stabilisation of CLK3 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID720336Millipore: Percentage of residual kinase activity of LYN at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1 mM Na3VO4, 0.1% ?-mercaptoethanol2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720324Millipore: Percentage of residual kinase activity of KDR at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720129Millipore: Percentage of residual kinase activity of EPHA4 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 10 mM MnCl22013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720323Millipore: Percentage of residual kinase activity of MAPK10 at 10uM relative to control. Control inhibitor: JAK Inhibitor I at 30.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1% ?-mercaptoethanol2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1224761Delta TM value showing the stabilisation of CLK1 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID720341Millipore: Percentage of residual kinase activity of MAPK1 at 10uM relative to control. Control inhibitor: ERK Inhibitor II at 30.0uM. Buffer: 25 mM Tris pH 7.5, 0.02 mM EGTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1224769Delta TM value showing the stabilisation of GSK3B produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1224805Delta TM value showing the stabilisation of VRK2 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID720288Millipore: Percentage of residual kinase activity of TAOK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720043Millipore: Percentage of residual kinase activity of PTK6 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 5 mM MnCl22013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720353Millipore: Percentage of residual kinase activity of MINK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720380Millipore: Percentage of residual kinase activity of MET at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720080Millipore: Percentage of residual kinase activity of CSNK1G2 at 10uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720330Millipore: Percentage of residual kinase activity of STK10 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720019Millipore: Percentage of residual kinase activity of ALK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720088Millipore: Percentage of residual kinase activity of CSNK2A2 at 10uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-1002013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720126Millipore: Percentage of residual kinase activity of EPHA2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720415Millipore: Percentage of residual kinase activity of WNK2 at 10uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720112Millipore: Percentage of residual kinase activity of DCLK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720456Millipore: Percentage of residual kinase activity of PASK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720087Millipore: Percentage of residual kinase activity of CSNK2A2 at 1uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-1002013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720260Millipore: Percentage of residual kinase activity of MAPK11 at 1uM relative to control. Control inhibitor: SB203580 at 100.0uM. Buffer: 25 mM Tris pH 7.5, 0.02 mM EGTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1224783Delta TM value showing the stabilisation of PAK6 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID720061Millipore: Percentage of residual kinase activity of CDK3 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720220Millipore: Percentage of residual kinase activity of PHKG2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720287Millipore: Percentage of residual kinase activity of TAOK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 50 mM NaCl2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720443Millipore: Percentage of residual kinase activity of NLK at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720366Millipore: Percentage of residual kinase activity of RPS6KA5 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720067Millipore: Percentage of residual kinase activity of CDK6 at 1uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID524790Antiplasmodial activity against Plasmodium falciparum 3D7 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID720059Millipore: Percentage of residual kinase activity of CDK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720420Millipore: Percentage of residual kinase activity of ZAP70 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1 mM Na3VO4, 0.1% ?-mercaptoethanol2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720039Millipore: Percentage of residual kinase activity of AURKC at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 50 mM NaCl, 0.1% v/v Triton-X-1002013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720253Millipore: Percentage of residual kinase activity of RPS6KA3 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1224791Delta TM value showing the stabilisation of PRKACA produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID720438Millipore: Percentage of residual kinase activity of NEK6 at 1uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720144Millipore: Percentage of residual kinase activity of EPHB4 at 10uM relative to control. Control inhibitor: PP2 at 30.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 10 mM MnCl22013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720417Millipore: Percentage of residual kinase activity of WNK3 at 10uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720270Millipore: Percentage of residual kinase activity of SGK3 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720110Millipore: Percentage of residual kinase activity of DAPK2 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720186Millipore: Percentage of residual kinase activity of HIPK1 at 10uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720227Millipore: Percentage of residual kinase activity of PIM3 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 0.1% Triton X-1002013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720469Millipore: Percentage of residual kinase activity of AKT2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720125Millipore: Percentage of residual kinase activity of EPHA2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720412Millipore: Percentage of residual kinase activity of VRK2 at 1uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1224802Delta TM value showing the stabilisation of TNIK produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID720175Millipore: Percentage of residual kinase activity of GRK5 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720289Millipore: Percentage of residual kinase activity of TAOK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720280Millipore: Percentage of residual kinase activity of PLK2 at 1uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720042Millipore: Percentage of residual kinase activity of AXL at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720377Millipore: Percentage of residual kinase activity of STK24 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720095Millipore: Percentage of residual kinase activity of CAMK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 0.5 mM CaCl2, 16 ug/mL calmodulin2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1224749Delta TM value showing the stabilisation of CAMK1D produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1224796Delta TM value showing the stabilisation of LOK produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID720337Millipore: Percentage of residual kinase activity of LYN at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1 mM Na3VO4, 0.1% ?-mercaptoethanol2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1224779Delta TM value showing the stabilisation of NEK6 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID720094Millipore: Percentage of residual kinase activity of CSK at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1 mM Na3VO4, 0.1% ?-mercaptoethanol, 10 mM MnCl22013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720051Millipore: Percentage of residual kinase activity of BRSK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720379Millipore: Percentage of residual kinase activity of MERTK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: mM MOPS pH 7.0, 0.2 mM EDTA, 30 mM NaCl2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720092Millipore: Percentage of residual kinase activity of CLK3 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720477Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720099Millipore: Percentage of residual kinase activity of CAMK2G at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 0.5 mM CaCl2, 16 ug/mL calmodulin2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720026Millipore: Percentage of residual kinase activity of PRKAA2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 200 uM AMP2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1224762Delta TM value showing the stabilisation of CLK2 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1224781Delta TM value showing the stabilisation of PAK4 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID720141Millipore: Percentage of residual kinase activity of EPHB3 at 1uM relative to control. Control inhibitor: PP2 at 30.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 10 mM MnCl22013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720365Millipore: Percentage of residual kinase activity of CDC42BPB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720211Millipore: Percentage of residual kinase activity of PRKG1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 10 uM cGMP2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720381Millipore: Percentage of residual kinase activity of MET at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720369Millipore: Percentage of residual kinase activity of RPS6KA4 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720058Millipore: Percentage of residual kinase activity of CDK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720188Millipore: Percentage of residual kinase activity of HIPK2 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720272Millipore: Percentage of residual kinase activity of SIK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1224760Delta TM value showing the stabilisation of CHEK2 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID720450Millipore: Percentage of residual kinase activity of PAK7 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1224801Delta TM value showing the stabilisation of MST1 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID720282Millipore: Percentage of residual kinase activity of SYK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1 mM Na3VO4, 0.1% ?-mercaptoethanol2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720078Millipore: Percentage of residual kinase activity of CSNK1G1 at 10uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720397Millipore: Percentage of residual kinase activity of TSSK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1224765Delta TM value showing the stabilisation of CK1G2 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1224804Delta TM value showing the stabilisation of VRK1 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID720091Millipore: Percentage of residual kinase activity of CLK3 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720329Millipore: Percentage of residual kinase activity of STK11 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 0.1% v/v Triton X-1002013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720307Millipore: Percentage of residual kinase activity of IRAK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720254Millipore: Percentage of residual kinase activity of RPS6KA2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720209Millipore: Percentage of residual kinase activity of PRKD2 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-1002013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720339Millipore: Percentage of residual kinase activity of MAPK3 at 10uM relative to control. Control inhibitor: ERK Inhibitor II at 30.0uM. Buffer: 25 mM Tris pH 7.5, 0.02 mM EGTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720277Millipore: Percentage of residual kinase activity of SRPK2 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720060Millipore: Percentage of residual kinase activity of CDK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1224758Delta TM value showing the stabilisation of CDK6 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID720020Millipore: Percentage of residual kinase activity of ALK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720370Millipore: Percentage of residual kinase activity of SRPK3 at 1uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720322Millipore: Percentage of residual kinase activity of MAPK10 at 1uM relative to control. Control inhibitor: JAK Inhibitor I at 30.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1% ?-mercaptoethanol2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1224753Delta TM value showing the stabilisation of CAMK2D produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID720281Millipore: Percentage of residual kinase activity of PLK2 at 10uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720161Millipore: Percentage of residual kinase activity of FGR at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720166Millipore: Percentage of residual kinase activity of FLT3 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720084Millipore: Percentage of residual kinase activity of CSNK1D at 10uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720145Millipore: Percentage of residual kinase activity of ERBB4 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 2.5 mM MnCl22013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720063Millipore: Percentage of residual kinase activity of CDK5 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720083Millipore: Percentage of residual kinase activity of CSNK1D at 1uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720427Millipore: Percentage of residual kinase activity of KIT at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 10 mM MnCl22013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1224794Delta TM value showing the stabilisation of RSK2b produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID720183Millipore: Percentage of residual kinase activity of GSK3B at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720404Millipore: Percentage of residual kinase activity of NTRK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720041Millipore: Percentage of residual kinase activity of AXL at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720168Millipore: Percentage of residual kinase activity of FLT4 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720409Millipore: Percentage of residual kinase activity of ULK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720314Millipore: Percentage of residual kinase activity of JAK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720362Millipore: Percentage of residual kinase activity of CDC42BPA at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720176Millipore: Percentage of residual kinase activity of GRK5 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720057Millipore: Percentage of residual kinase activity of CDK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720425Millipore: Percentage of residual kinase activity of RAF1 at 10uM relative to control. Control inhibitor: SB203580 at 100.0uM. Buffer: 25 mM Tris pH 7.5, 0.02 mM EGTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720180Millipore: Percentage of residual kinase activity of GRK7 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720292Millipore: Percentage of residual kinase activity of TBK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720195Millipore: Percentage of residual kinase activity of HCK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720358Millipore: Percentage of residual kinase activity of MYLK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 0.5 mM CaCl2, 16 ug/mL calmodulin2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1224777Delta TM value showing the stabilisation of MST4(1) produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID720422Millipore: Percentage of residual kinase activity of DAPK3 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720347Millipore: Percentage of residual kinase activity of MARK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1224807Delta TM value showing the stabilisation of YSK1 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID720221Millipore: Percentage of residual kinase activity of PHKG2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720454Millipore: Percentage of residual kinase activity of MARK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720383Millipore: Percentage of residual kinase activity of MKNK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720393Millipore: Percentage of residual kinase activity of TLK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720484Millipore: Percentage of residual kinase activity of PRKCZ at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720090Millipore: Percentage of residual kinase activity of CLK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720073Millipore: Percentage of residual kinase activity of CHEK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720257Millipore: Percentage of residual kinase activity of RPS6KA6 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 30 mM NaCl2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720086Millipore: Percentage of residual kinase activity of CSNK2A1 at 10uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-1002013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720449Millipore: Percentage of residual kinase activity of PAK4 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1224771Delta TM value showing the stabilisation of MEK2 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1224789Delta TM value showing the stabilisation of PLK1 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID720049Millipore: Percentage of residual kinase activity of BMX at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720197Millipore: Percentage of residual kinase activity of IGF1R at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1 mM Na3VO4, 0.1% ?-mercaptoethanol2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720219Millipore: Percentage of residual kinase activity of FRK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720474Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720334Millipore: Percentage of residual kinase activity of LCK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720024Millipore: Percentage of residual kinase activity of PRKAA1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 200 uM AMP2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720276Millipore: Percentage of residual kinase activity of SRPK2 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720290Millipore: Percentage of residual kinase activity of TAOK3 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 200 mM NaCl, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720202Millipore: Percentage of residual kinase activity of PRKCQ at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1224776Delta TM value showing the stabilisation of ERK3 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID720056Millipore: Percentage of residual kinase activity of CDK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720283Millipore: Percentage of residual kinase activity of SYK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1 mM Na3VO4, 0.1% ?-mercaptoethanol2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720401Millipore: Percentage of residual kinase activity of TEK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 0.5 mM MnCl22013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720248Millipore: Percentage of residual kinase activity of TYRO3 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 1 mM MnCl22013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720382Millipore: Percentage of residual kinase activity of MKNK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720172Millipore: Percentage of residual kinase activity of FYN at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1 mM Na3VO42013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720445Millipore: Percentage of residual kinase activity of PAK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720229Millipore: Percentage of residual kinase activity of PLK1 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 20 mM DTT2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720284Millipore: Percentage of residual kinase activity of MAP3K7 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720410Millipore: Percentage of residual kinase activity of ULK3 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720399Millipore: Percentage of residual kinase activity of TEC at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 1 mM Na3VO4, 5 mM Na-?-glycerophosphate2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1224750Delta TM value showing the stabilisation of CAMK1G produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID720111Millipore: Percentage of residual kinase activity of DCLK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720342Millipore: Percentage of residual kinase activity of MAPKAPK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Na-?-glycerophosphate pH 7.5, 0.1 mM EGTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720355Millipore: Percentage of residual kinase activity of MAP2K6 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1% ?-mercaptoethanol, 0.1 mM Na3VO4, 1 mg/mL BSA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720251Millipore: Percentage of residual kinase activity of RPS6KA1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720271Millipore: Percentage of residual kinase activity of SGK3 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720160Millipore: Percentage of residual kinase activity of FES at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720441Millipore: Percentage of residual kinase activity of NEK7 at 10uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1224800Delta TM value showing the stabilisation of MST4 (2) produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID720205Millipore: Percentage of residual kinase activity of PRKCI at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-1002013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720303Millipore: Percentage of residual kinase activity of INSR at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1 mM Na3VO4, 0.1% ?-mercaptoethanol2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720225Millipore: Percentage of residual kinase activity of PIM2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720169Millipore: Percentage of residual kinase activity of CSF1R at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720164Millipore: Percentage of residual kinase activity of FLT1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720352Millipore: Percentage of residual kinase activity of MINK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720408Millipore: Percentage of residual kinase activity of ULK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1224766Delta TM value showing the stabilisation of CK1G3 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID720121Millipore: Percentage of residual kinase activity of EGFR at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 10 mM MnCl22013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720224Millipore: Percentage of residual kinase activity of PIM2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720262Millipore: Percentage of residual kinase activity of MAPK12 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 25 mM Tris pH 7.5, 0.02 mM EGTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720116Millipore: Percentage of residual kinase activity of DMPK at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720374Millipore: Percentage of residual kinase activity of STK3 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720458Millipore: Percentage of residual kinase activity of PDGFRA at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720054Millipore: Percentage of residual kinase activity of BRSK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720233Millipore: Percentage of residual kinase activity of PRKX at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720459Millipore: Percentage of residual kinase activity of PDGFRA at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1224759Delta TM value showing the stabilisation of CDKL1 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID720187Millipore: Percentage of residual kinase activity of HIPK2 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720344Millipore: Percentage of residual kinase activity of MAPKAPK3 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Na-?-glycerophosphate pH 7.5, 0.1 mM EGTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720155Millipore: Percentage of residual kinase activity of FGFR4 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 10 mM MnCl22013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720072Millipore: Percentage of residual kinase activity of CDK9 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1224786Delta TM value showing the stabilisation of PIM1 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID720297Millipore: Percentage of residual kinase activity of IGF1R at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 1 mM Na3VO4, 5 mM Na-?-glycerophosphate2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1224806Delta TM value showing the stabilisation of VRK3 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID720130Millipore: Percentage of residual kinase activity of EPHA4 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 10 mM MnCl22013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720394Millipore: Percentage of residual kinase activity of TSSK1B at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1224797Delta TM value showing the stabilisation of MPSK1 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID720328Millipore: Percentage of residual kinase activity of STK11 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 0.1% v/v Triton X-1002013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720447Millipore: Percentage of residual kinase activity of PAK3 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720053Millipore: Percentage of residual kinase activity of BRSK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720177Millipore: Percentage of residual kinase activity of GRK6 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720316Millipore: Percentage of residual kinase activity of JAK3 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720182Millipore: Percentage of residual kinase activity of GSK3A at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720398Millipore: Percentage of residual kinase activity of TEC at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 1 mM Na3VO4, 5 mM Na-?-glycerophosphate2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720198Millipore: Percentage of residual kinase activity of IGF1R at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1 mM Na3VO4, 0.1% ?-mercaptoethanol2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720237Millipore: Percentage of residual kinase activity of RIPK2 at 10uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720309Millipore: Percentage of residual kinase activity of IRAK4 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720326Millipore: Percentage of residual kinase activity of LIMK1 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720241Millipore: Percentage of residual kinase activity of ROCK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720392Millipore: Percentage of residual kinase activity of TLK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1224756Delta TM value showing the stabilisation of CAMKK2 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID720137Millipore: Percentage of residual kinase activity of EPHB1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720285Millipore: Percentage of residual kinase activity of MAP3K7 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720299Millipore: Percentage of residual kinase activity of CHUK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720232Millipore: Percentage of residual kinase activity of PRKX at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720135Millipore: Percentage of residual kinase activity of EPHA8 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720313Millipore: Percentage of residual kinase activity of ITK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720402Millipore: Percentage of residual kinase activity of NTRK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720451Millipore: Percentage of residual kinase activity of PAK7 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720432Millipore: Percentage of residual kinase activity of MTOR at 1uM relative to control. Control inhibitor: PI-103 at 30.0uM. Buffer: 50 mM HEPES pH 7.5, 1 mM EGTA, 0.01% Tween 202013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID325676Inhibition of p38 MAP kinase2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID720375Millipore: Percentage of residual kinase activity of STK3 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720411Millipore: Percentage of residual kinase activity of ULK3 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720325Millipore: Percentage of residual kinase activity of KDR at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720031Millipore: Percentage of residual kinase activity of ABL1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720089Millipore: Percentage of residual kinase activity of CLK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720446Millipore: Percentage of residual kinase activity of PAK3 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720167Millipore: Percentage of residual kinase activity of FLT4 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720378Millipore: Percentage of residual kinase activity of MERTK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: mM MOPS pH 7.0, 0.2 mM EDTA, 30 mM NaCl2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720429Millipore: Percentage of residual kinase activity of SRC at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1611955Inhibition of tyrosinase in mouse B16F10 cells assessed as reduction in melanin synthesis after 2 hrs by spectrophotometric analysis2018Journal of medicinal chemistry, 09-13, Volume: 61, Issue:17
Inhibitors of Melanogenesis: An Updated Review.
AID720132Millipore: Percentage of residual kinase activity of EPHA5 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 2.5 mM MnCl22013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720124Millipore: Percentage of residual kinase activity of EPHA1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720200Millipore: Percentage of residual kinase activity of PRKCH at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720216Millipore: Percentage of residual kinase activity of PKN2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1% ?-mercaptoethanol2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720244Millipore: Percentage of residual kinase activity of MST1R at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720345Millipore: Percentage of residual kinase activity of MAPKAPK3 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Na-?-glycerophosphate pH 7.5, 0.1 mM EGTA2013The Biochemical journal, Apr-15, Volume: 451, Issue:2
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347160Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347169Tertiary RLuc qRT-PCR qHTS assay for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347157Confirmatory screen GU Rhodamine qHTS for Zika virus inhibitors qHTS2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347159Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347161Confirmatory screen NINDS Rhodamine qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).2014Journal of biomolecular screening, Jul, Volume: 19, Issue:6
A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (117)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's71 (60.68)29.6817
2010's38 (32.48)24.3611
2020's8 (6.84)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 21.28

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index21.28 (24.57)
Research Supply Index4.79 (2.92)
Research Growth Index5.48 (4.65)
Search Engine Demand Index21.17 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (21.28)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews2 (1.68%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other117 (98.32%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]